Consun Pharmaceutical Group Ltd. (HK:1681)
:1681
Want to see HK:1681 full AI Analyst Report?
Top Page
Consun Pharmaceutical Group Ltd.
(1681)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$19.50
▲(19.56% Upside)
Action:ReiteratedDate:10/31/25
Consun Pharmaceutical Group Ltd. exhibits strong financial performance with robust revenue growth and profitability. The stock's valuation is attractive with a reasonable P/E ratio and a solid dividend yield. However, technical indicators suggest weak momentum, which could pose short-term challenges.
Positive Factors
Consistent strong revenue growth
Sustained ~19% revenue growth and a multi-year increase through 2019–2024 indicate expanding product penetration in core hospital channels. This durable top-line expansion supports scale benefits, long-term R&D funding, and continued commercial leverage across therapeutic franchises.
Negative Factors
Limited recent cash flow visibility
Historical free cash flow has been positive, but absent recent cash flow detail creates uncertainty about current cash conversion and sustainability. This reduces confidence in funding capacity for R&D, dividends or M&A without relying on balance sheet reserves.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent strong revenue growth
Sustained ~19% revenue growth and a multi-year increase through 2019–2024 indicate expanding product penetration in core hospital channels. This durable top-line expansion supports scale benefits, long-term R&D funding, and continued commercial leverage across therapeutic franchises.
Read all positive factors
Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$12.93B
Dividend Yield3.93%
Average Volume (3M)2.00M
Price to Earnings (P/E)11.3
Beta (1Y)0.57
Revenue Growth15.28%
EPS Growth14.76%
CountryHK
Employees3,164
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.75
Shares Outstanding841,547,100
10 Day Avg. Volume1,421,042
30 Day Avg. Volume1,998,301
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)1.53
Price to Sales (P/S)2.12
P/FCF Ratio6.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$24.23Price Target Upside48.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.43
Revenue Forecast (FY)HK$3.88B
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People's Republic of China. The company operates through two segment...
How the Company Makes Money
Consun Pharmaceutical Group Ltd. generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which include both traditional Chinese medicines and modern pharmaceuticals. The company leverages its robust rese...
Consun Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.27B | 2.97B | 2.59B | 2.34B | 2.04B | 1.75B |
| Gross Profit | 2.50B | 2.24B | 1.92B | 1.76B | 1.53B | 1.32B |
| EBITDA | 1.14B | 1.05B | 963.06M | 785.89M | 728.71M | 618.79M |
| Net Income | 1.01B | 910.46M | 784.53M | 682.91M | 590.17M | 498.79M |
Balance Sheet | ||||||
| Total Assets | 6.09B | 5.85B | 5.51B | 4.89B | 4.36B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 4.04B | 3.87B | 3.58B | 3.04B | 2.43B | 1.94B |
| Total Debt | 253.35M | 267.17M | 511.53M | 460.18M | 610.97M | 549.41M |
| Total Liabilities | 1.45B | 1.46B | 1.59B | 1.45B | 1.45B | 1.43B |
| Stockholders Equity | 4.35B | 4.10B | 3.63B | 3.15B | 2.62B | 2.22B |
Cash Flow | ||||||
| Free Cash Flow | 1.14B | 977.99M | 766.41M | 896.09M | 627.29M | 818.36M |
| Operating Cash Flow | 1.23B | 1.09B | 818.97M | 947.68M | 725.54M | 867.06M |
| Investing Cash Flow | -901.34M | -186.91M | -231.77M | -368.80M | -298.31M | -25.70M |
| Financing Cash Flow | -652.30M | -729.26M | -280.10M | -342.20M | -166.66M | -279.80M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Negative
16.31
Price Trends
17.30
Negative
16.53
Negative
15.39
Positive
Market Momentum
-0.18
Positive
42.58
Neutral
15.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Negative. The current price of 16.31 is below the 20-day moving average (MA) of 16.68, below the 50-day MA of 17.30, and above the 200-day MA of 15.39, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 42.58 is Neutral, neither overbought nor oversold. The STOCH value of 15.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1681.
Consun Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | HK$7.31B | 6.31 | 11.90% | 5.80% | -17.03% | 12.82% | |
72 Outperform | HK$12.93B | 11.34 | 24.04% | 3.93% | 15.28% | 14.76% | |
58 Neutral | HK$9.43B | 30.68 | 5.62% | 4.47% | 3.34% | -39.43% | |
54 Neutral | HK$8.61B | -28.37 | -1.64% | 3.66% | -10.68% | -737.07% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$12.32B | 34.17 | 3.49% | 0.87% | 37.90% | ― |
* Healthcare Sector Average
HK:1681
Consun Pharmaceutical Group Ltd.
16.11
7.28
82.51%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.67
-0.27
-14.01%
HK:0460
Sihuan Pharmaceutical Holdings Group
1.31
0.60
83.22%
HK:2877
China Shineway Pharmaceutical Group Limited
9.78
2.64
36.97%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
6.18
0.92
17.54%
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharma Expands Share Buyback to HKD300 Million Amid Confidence in Growth Outlook
Jan 29, 2026
Consun Pharmaceutical Group Limited has expanded its existing share repurchase initiative, authorising an additional HKD100 million in buybacks under its current mandate, bringing the total potential repurchase scale to up to HKD300 million, or no...
Consun Pharmaceutical Tightens ESG Governance With Updated Committee Mandate
Dec 23, 2025
Consun Pharmaceutical Group Ltd. has formalised and updated the terms of reference for its Environmental, Social and Governance (ESG) Committee, effective 23 December 2025, to align with Hong Kong Listing Rules and strengthen oversight of ESG and ...
Consun Pharmaceutical Shareholders Approve New Award Scheme and Amended Governance Documents at EGM
Dec 23, 2025
Consun Pharmaceutical Group Limited announced that all resolutions proposed at its extraordinary general meeting held on 23 December 2025 were duly approved by shareholders by way of poll, with all directors attending in person or via video confer...
Consun Pharmaceutical Group to Discuss New Share Award Scheme and Amendments
Dec 8, 2025
Consun Pharmaceutical Group Limited has announced an extraordinary general meeting to discuss and potentially approve a new share award scheme. This scheme aims to issue up to 84,281,191 shares to eligible participants, including a sublimit of 8,4...
Consun Pharmaceutical Schedules EGM for Share Scheme and Governance Amendments
Dec 2, 2025
Consun Pharmaceutical Group Ltd. has announced the scheduling of an Extraordinary General Meeting (EGM) on December 23, 2025, to discuss and approve the proposed adoption of a Share Award Scheme and amendments to its memorandum and articles of ass...
Consun Pharmaceutical Proposes New Share Award Scheme
Nov 6, 2025
Consun Pharmaceutical Group Ltd. has proposed the adoption of a Share Award Scheme to incentivize and reward participants for the growth and development of the company. This scheme, which requires shareholder approval, aims to grant new shares und...
Consun Pharmaceutical Proposes Amendments to Memorandum for Treasury Shares
Nov 6, 2025
Consun Pharmaceutical Group Limited, a company incorporated in the Cayman Islands, has announced proposed amendments to its existing memorandum and articles of association. These amendments aim to allow the company to hold and dispose of repurchas...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.